Palbonix 125 mg contains Palbociclib, an orally administered targeted anticancer agent belonging to the class of cyclin-dependent kinase (CDK) 4/6 inhibitors. It is widely used in the treatment of hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer. Palbonix plays a key role in controlling tumor cell proliferation by interrupting critical cell cycle pathways that drive cancer growth.

Palbociclib works by selectively inhibiting CDK4 and CDK6, enzymes that regulate progression from the G1 phase to the S phase of the cell cycle. In HR-positive breast cancer, these kinases are often overactive, leading to uncontrolled cell division. By blocking CDK4/6 activity, Palbonix causes cell cycle arrest, thereby slowing tumor growth and enhancing the effectiveness of endocrine (hormonal) therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Palbonix 125 mg is indicated for:

• Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.

• Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy.

Therapeutic Class

• Antineoplastic Agent

• Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor

Pharmacology

Palbociclib selectively targets CDK4 and CDK6, preventing phosphorylation of the retinoblastoma (Rb) protein. This inhibition halts cell cycle progression and reduces cancer cell proliferation. Palbonix does not typically cause direct tumor cell death but instead suppresses tumor growth, making it highly effective when used alongside hormonal therapies.

Following oral administration, Palbociclib is well absorbed and reaches steady-state levels with regular dosing. Its pharmacokinetic profile supports once-daily administration in defined treatment cycles.

Dosage and Administration

• Palbonix 125 mg is taken orally once daily for 21 consecutive days followed by 7 days off, completing a 28-day treatment cycle.

• The capsule should be taken with food, preferably at the same time each day.

• Dose modifications may be required based on blood count results and patient tolerability.

• Regular monitoring of complete blood counts is essential, especially during the first few treatment cycles.

Key Benefits

• Proven efficacy in HR-positive, HER2-negative breast cancer.

• Enhances the effectiveness of endocrine therapy.

• Oral treatment with structured dosing cycles.

• Helps delay disease progression and improve progression-free survival.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Neutropenia is a common adverse effect; frequent blood count monitoring is required.

• Use with caution in patients with hepatic impairment.

• Avoid use during pregnancy and breastfeeding due to potential fetal risk.

• Drug interactions may occur with strong CYP3A inhibitors or inducers.

Adverse Effects

Common adverse effects include neutropenia, leukopenia, fatigue, nausea, stomatitis, diarrhea, alopecia, and upper respiratory tract infections. Most adverse reactions are manageable with dose adjustments and supportive care.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Palbonix 125 mg offers a well-established and effective targeted therapy option for patients with advanced breast cancer, providing disease control through precise inhibition of cell cycle progression.